FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292362016> ?p ?o ?g. }

• W4292362016 endingPage "116" @default.
• W4292362016 startingPage "109" @default.
• W4292362016 abstract "We studied the feasibility of using the α-emitting 213Bi-anti-CD20 therapy with direct bioluminescent tracking of micrometastatic human B-cell lymphoma in a SCID mouse model. Methods: A highly lethal SCID mouse model of minimal-tumor-burden disseminated non-Hodgkin lymphoma (NHL) was established using human Raji lymphoma cells transfected to express the luciferase reporter. In vitro and in vivo radioimmunotherapy experiments were conducted. Single- and multiple-dose regimens were explored, and results with 213Bi-rituximab were compared with various controls, including no treatment, free 213Bi radiometal, unlabeled rituximab, and 213Bi-labeled anti-HER2/neu (non-CD20-specific antibody). 213Bi-rituximab was also compared in vivo with the low-energy β-emitter 131I-tositumomab and the high-energy β-emitter 90Y-rituximab. Results: In vitro studies showed dose-dependent target-specific killing of lymphoma cells with 213Bi-rituximab. Multiple in vivo studies showed significant and specific tumor growth delays with 213Bi-rituximab versus free 213Bi, 213Bi-labeled control antibody, or unlabeled rituximab. Redosing of 213Bi-rituximab was more effective than single dosing. With a single dose of therapy given 4 d after intravenous tumor inoculation, disease in all untreated controls, and in all mice in the 925-kBq 90Y-rituximab group, progressed. With 3,700 kBq of 213Bi-rituximab, 75% of the mice survived and all but 1 survivor was cured. With 2,035 kBq of 131I-tositumomab, 75% of the mice were tumor-free by bioluminescent imaging and 62.5% survived. Conclusion: Cure of micrometastatic NHL is achieved in most animals treated 4 d after intravenous tumor inoculation using either 213Bi-rituximab or 131I-tositumomab, in contrast to the lack of cures with unlabeled rituximab or 90Y-rituximab or if there was a high tumor burden before radioimmunotherapy. α-emitter-labeled anti-CD20 antibodies are promising therapeutics for NHL, although a longer-lived α-emitter may be of greater efficacy." @default.
• W4292362016 created "2022-08-20" @default.
• W4292362016 creator A5002401816 @default.
• W4292362016 creator A5008024688 @default.
• W4292362016 creator A5018382697 @default.
• W4292362016 creator A5021960666 @default.
• W4292362016 creator A5024722162 @default.
• W4292362016 creator A5027603351 @default.
• W4292362016 creator A5068293939 @default.
• W4292362016 creator A5078161354 @default.
• W4292362016 date "2022-08-18" @default.
• W4292362016 modified "2023-10-14" @default.
• W4292362016 title "Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using²¹³Bi-Anti-CD20 Monoclonal Antibody" @default.
• W4292362016 cites W1831034898 @default.
• W4292362016 cites W1834394418 @default.
• W4292362016 cites W1972256368 @default.
• W4292362016 cites W1982852535 @default.
• W4292362016 cites W1985594788 @default.
• W4292362016 cites W1992721289 @default.
• W4292362016 cites W2006928831 @default.
• W4292362016 cites W2007820781 @default.
• W4292362016 cites W2012058153 @default.
• W4292362016 cites W2014654561 @default.
• W4292362016 cites W2043910284 @default.
• W4292362016 cites W2046534114 @default.
• W4292362016 cites W2058426435 @default.
• W4292362016 cites W2072475957 @default.
• W4292362016 cites W2083752055 @default.
• W4292362016 cites W2098478084 @default.
• W4292362016 cites W2106946113 @default.
• W4292362016 cites W2117550271 @default.
• W4292362016 cites W2123987346 @default.
• W4292362016 cites W2126539571 @default.
• W4292362016 cites W2137869150 @default.
• W4292362016 cites W2141454098 @default.
• W4292362016 cites W21498029 @default.
• W4292362016 cites W2155695403 @default.
• W4292362016 cites W2164532418 @default.
• W4292362016 cites W2767946527 @default.
• W4292362016 cites W3207718587 @default.
• W4292362016 doi "https://doi.org/10.2967/jnumed.122.263962" @default.
• W4292362016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35981897" @default.
• W4292362016 hasPublicationYear "2022" @default.
• W4292362016 type Work @default.
• W4292362016 citedByCount "2" @default.
• W4292362016 countsByYear W42923620162022 @default.
• W4292362016 countsByYear W42923620162023 @default.
• W4292362016 crossrefType "journal-article" @default.
• W4292362016 hasAuthorship W4292362016A5002401816 @default.
• W4292362016 hasAuthorship W4292362016A5008024688 @default.
• W4292362016 hasAuthorship W4292362016A5018382697 @default.
• W4292362016 hasAuthorship W4292362016A5021960666 @default.
• W4292362016 hasAuthorship W4292362016A5024722162 @default.
• W4292362016 hasAuthorship W4292362016A5027603351 @default.
• W4292362016 hasAuthorship W4292362016A5068293939 @default.
• W4292362016 hasAuthorship W4292362016A5078161354 @default.
• W4292362016 hasBestOaLocation W42923620161 @default.
• W4292362016 hasConcept C150903083 @default.
• W4292362016 hasConcept C159654299 @default.
• W4292362016 hasConcept C18031839 @default.
• W4292362016 hasConcept C203014093 @default.
• W4292362016 hasConcept C207001950 @default.
• W4292362016 hasConcept C2776146153 @default.
• W4292362016 hasConcept C2779338263 @default.
• W4292362016 hasConcept C2780653079 @default.
• W4292362016 hasConcept C502942594 @default.
• W4292362016 hasConcept C542903549 @default.
• W4292362016 hasConcept C71924100 @default.
• W4292362016 hasConcept C86803240 @default.
• W4292362016 hasConceptScore W4292362016C150903083 @default.
• W4292362016 hasConceptScore W4292362016C159654299 @default.
• W4292362016 hasConceptScore W4292362016C18031839 @default.
• W4292362016 hasConceptScore W4292362016C203014093 @default.
• W4292362016 hasConceptScore W4292362016C207001950 @default.
• W4292362016 hasConceptScore W4292362016C2776146153 @default.
• W4292362016 hasConceptScore W4292362016C2779338263 @default.
• W4292362016 hasConceptScore W4292362016C2780653079 @default.
• W4292362016 hasConceptScore W4292362016C502942594 @default.
• W4292362016 hasConceptScore W4292362016C542903549 @default.
• W4292362016 hasConceptScore W4292362016C71924100 @default.
• W4292362016 hasConceptScore W4292362016C86803240 @default.
• W4292362016 hasIssue "1" @default.
• W4292362016 hasLocation W42923620161 @default.
• W4292362016 hasLocation W42923620162 @default.
• W4292362016 hasLocation W42923620163 @default.
• W4292362016 hasOpenAccess W4292362016 @default.
• W4292362016 hasPrimaryLocation W42923620161 @default.
• W4292362016 hasRelatedWork W2037772145 @default.
• W4292362016 hasRelatedWork W2073341443 @default.
• W4292362016 hasRelatedWork W2093530235 @default.
• W4292362016 hasRelatedWork W2148853365 @default.
• W4292362016 hasRelatedWork W2159173527 @default.
• W4292362016 hasRelatedWork W2187300573 @default.
• W4292362016 hasRelatedWork W2408094891 @default.
• W4292362016 hasRelatedWork W2845298299 @default.
• W4292362016 hasRelatedWork W4296705196 @default.
• W4292362016 hasRelatedWork W2162231793 @default.
• W4292362016 hasVolume "64" @default.

• next